Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses

Zining Jin¹, Lu Xu², Lei Zhang³, Min Zhao¹, Dongbao Li², Lijun Ye¹, Ying Ma¹, Siyu Ren¹, Hailan Yu¹, Danyu Wang², Chunyan Liang¹, Bo Chen¹

Departments of ¹Breast Surgery, ²Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

Received January 17, 2018; Accepted June 1, 2018; Epub June 15, 2018; Published June 30, 2018

Abstract: Interleukin enhancer binding factor 2 (ILF2) participates in several aspects of DNA and RNA metabolism and regulates gene expression at multiple levels; however, its role in breast cancer remains undefined. The variant statuses of ILF2 in human breast cancer were evaluated using the COSMIC database. Altered ILF2 expression in normal breast tissue relative to cancer tissue and in breast cancer patients with different clinicopathological characteristics, molecular subtypes, clinical outcomes and chemotherapy responses were examined using the Oncomine, GOBO, Kaplan-Meier plotter and GEO datasets. To explore possible biological networks connected to ILF2 in breast cancer, we performed ingenuity pathway analysis on ILF2-related differentially expressed genes. We found that many breast cancers had increased ILF2 copy number variations and increased ILF2 expression. We also observed that elevated ILF2 expression was correlated with aggressive features, such as high histological grade, BRCA1 mutations, and the triple-negative/basal-like subtype, which resulted in shorter survival in these cases. Moreover, ILF2 expression predicted responses to anthracycline/taxane-based treatment. Ingenuity pathway analysis revealed that ILF2-related biological functions included promoting cell survival, viability, and proliferation, as well as cell cycle progression and DNA repair. Certain well-known oncogenes (MYC and HGF), cytokines (CSF2, IFNG and IL5) and microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer. In summary, ILF2 is involved in the development and progression of breast cancer and may be a predictive biomarker for better responses to anthracycline/taxane-based treatments.

Keywords: ILF2, breast cancer, prognostic biomarker, predictive biomarker, neoadjuvant chemotherapy, pathway analysis

Introduction

Breast cancer is the most frequently diagnosed cancer among women and was the cause of an estimated 522,000 deaths worldwide in 2012 [1]. However, because of the biological complexity of breast cancer, it is often difficult to determine therapeutic responses, metastatic patterns, and clinical outcomes using only clinical parameters or classic pathological markers (oestrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2], and Ki-67) [2]. Identifying new and effective biomarkers might offer an enhanced perspective on the clinical behaviour of breast cancer and/or provide new therapeutic targets.

Interleukin enhancer binding factor 2 (ILF2, also known as NF45) was initially identified as a member of the transcriptional activator complex that is crucial for interleukin 2 expression in T cells [3]. ILF2 was later found to be ubiquitously expressed in human tissues and, together with its binding partner NF90 (ILF3), to participate in multiple aspects of DNA and RNA metabolism, including DNA repair and replication [4, 5], transcription [6], translation [7, 8], mRNA splicing [9], micro-RNA biogenesis [10-12], and viral replication [13, 14]. Silencing ILF2 leads to mitotic defects that can be partially explained by inhibiting DNA synthesis [15] and downregulating the translation of X-linked inhibitor of apoptosis (XIAP) and cellular inhibition of apoptosis protein 1 (cIAP1) mRNAs by reducing...
Clinicopathological significance of ILF2 in breast cancer

ILF2 IRES trans-acting protein factor activity [7, 8]. Recently, several studies have investigated the role of ILF2 in cancer and found that ILF2 is involved in the progression of various cancer types, such as pancreatic carcinoma [16, 17], hepatocellular carcinoma [12, 18], non-small cell lung cancer [19], oesophageal squamous cell carcinoma [20], and gastric cancer [21]. Although previous studies have demonstrated that certain ILF2 functions are cell type-dependent [14, 22], the precise role of ILF2 in breast cancer remains undefined. NF90, a crucial regulator and binding partner of ILF2, was recently reported to promote breast cancer tumourigenicity by activating urokinase-type plasminogen activator (uPA) transcription and inhibiting the processing of uPA mRNA-targeted microRNAs [23]. Based on these data, we hypothesized that ILF2 may also play a role in breast cancer progression.

This study used publicly available clinical datasets to identify correlations between ILF2 expression and breast cancer prognoses. Our findings are the first to demonstrate that elevated ILF2 expression is associated with breast cancer development and poor clinical outcomes. Higher ILF2 expression was observed in triple-negative and basal-like breast cancers and predicted responses to anthracycline/taxane-based neoadjuvant chemotherapy. Finally, ingenuity pathway analysis (IPA) was used to analyse transcriptional changes downstream of increased ILF2 expression to further explore the molecular mechanisms underlying the association between increased ILF2 expression and aggressive behaviours in breast cancer.

Materials and methods

Catalogue of somatic mutations in cancer (COSMIC) database

The COSMIC database is a high-resolution resource for exploring the impact of somatic mutations in human cancer (http://cancer.sanger.ac.uk) [24]. The latest release (COSMIC v81) was used to find the variant ILF2 statuses in human breast cancer.

Oncomine

The Oncomine platform (https://www.oncomine.org/; version 4.5) is a cancer microarray database that includes the gene expression profile data of 91,866 samples from 729 datasets [25]. Alterations in ILF2 mRNA expression were evaluated for normal breast tissues and breast cancers of different clinicopathological characteristics. Differences between groups were assessed by P-values complemented by fold change. To study the relative expression of ILF2 and cell cycle regulators, microarray data of 593 breast cancer cases from The Cancer Genome Atlas (TCGA) breast dataset were downloaded from Oncomine and analysed by linear regression.

Gene expression-based outcome for breast cancer online (GOBO)

GOBO (http://co.bmc.lu.se/gobo) is a web-based analysis tool that uses Affymetrix U133A microarray gene expression data from 1,881 breast cancer patients and a 51-sample breast cancer cell line set [26]. We used the Gene Set Analysis (GSA) tumour to explore ILF2 expression levels in different molecular subtypes and histological grades.

Kaplan-Meier plotter

The prognostic value of ILF2 was determined by Kaplan-Meier analysis using the Kaplan-Meier plotter.
Clinicopathological significance of ILF2 in breast cancer

Meier-plotter online software (http://kmplot.com/analysis/) with 5,143 breast cancer patients with a mean follow-up of 69 months [27]. To analyse relapse-free survival (RFS), overall survival (OS) and distant metastasis-free survival (DMFS), the patient samples were first split into two groups according to the median level of ILF2 expression. If no obvious effect was found, the software identified the best cut-off for the separation of patients into high- and low-expressing groups and calculated the hazard ratio with 95% confidence intervals and the log-rank P-value.

**Clinical datasets, gene expression profiling and functional annotation**

Raw data from three publicly available datasets focusing on anthracycline/taxane-based neoadjuvant chemotherapy responses were downloaded from Gene Expression Omnibus (GEO) with the accession numbers GSE25055 [28], GSE25065 [28] and GSE20194 [29]. The classification performance of ILF2 expression level was assessed by constructing a receiver operating characteristic (ROC) curve in SPSS version 18 (IBM, Armonk, NY, USA), and the predictive power was evaluated using the area under the ROC curve. Two-sided P-values < 0.05 were considered statistically significant.

To explore the possible molecular functions and biological networks of ILF2, the samples in GSE25055 and GSE25065 were split into two groups according to high (top 25%) and low (bottom 25%) ILF2 expression. A total of 592 genes that had a log fold change ≥ 1 and a
Clinicopathological significance of ILF2 in breast cancer

P-value < 0.05 were considered significantly differentially expressed and were imported into IPA [30] (http://www.ingenuity.com), such that biological functions and diseases or canonical pathways of which ILF2 may participate could be inferred. Moreover, “Upstream analysis” and “Causal network analysis” were performed to identify molecules that were upstream regulators of ILF2 and could possibly explain the observed expression changes.

Results

ILF2 variants in human cancers

The variant statuses of ILF2 were examined in 29,379 cancer patients over 39 different types of cancer. Although only 16 cancer types possessed complete information for “Point

Mutations”, “Copy Number Variations” and “Gene Expression”, the frequencies of ILF2 variants in these patients are shown in Figure 1. The frequency of point mutations was not high, i.e., < 1%, in any cancer type. A gain in ILF2 copy number was observed in several cancer types, such as tumors of the breast, lung, endometrium and urinary tract. The highest copy number variation frequency was 3.14%, which was found in breast cancer (among 1,749 patients). An overall trend towards increased ILF2 expression in tumors was noted compared with the population norm. Taken together, the alterations in the copy number and gene expression suggested that ILF2 might participate in breast cancer development.

High ILF2 expression is correlated with aggressive breast cancer phenotypes

To confirm that ILF2 expression was elevated in breast cancer, another dataset with a larger sample size was selected. Analysis of the Curtis breast dataset, which includes 2,136 clinical samples from the Oncomine database, showed significantly higher ILF2 expression in different histological breast cancer subtypes compared with normal breast tissue (Figure 2A). Moreover, elevated ILF2 expression was observed in high histological grade breast cancer using GOBO analysis (P ≤ 0.00001; Figure 2B). Several datasets in the Oncomine database presented similar results (P < 0.05). The results of two clinical cohorts with the largest sample sizes are shown in Figure 2C and 2D.
Clinicopathological significance of ILF2 in breast cancer

analysis showed that \textit{ILF2} expression was significantly higher in ER-negative than ER-positive breast cancers ($P \leq 0.00001$; Figure 3A). When investigating PAM50 intrinsic subtyping, the highest \textit{ILF2} expression was observed in basal-like tissues (Figure 3B). To further confirm the distribution of \textit{ILF2} expression in different breast cancer molecular subtypes, biomarker analysis was performed in the Oncomine database. Using six clinical cohorts, this analysis found that increased \textit{ILF2} expression was significantly associated with triple negative breast cancer (TNBC) compared with the other molecular subtypes (fold change > 1.5, $P < 0.05$). The pooled results of the six clinical cohorts showed a significant increase in \textit{ILF2} expression in TNBC ($P = 0.011$; Figure 3C); detailed information for each comparison is presented in Table 1. In summary, these findings indicated that elevated \textit{ILF2} expression was correlated with more aggressive breast cancer subtypes, such as TNBC and basal-like breast cancer.

\textit{High ILF2 expression was correlated with poor prognoses}

We further examined the influence of \textit{ILF2} on the long-term survival of breast cancer patients.
Clinicopathological significance of ILF2 in breast cancer

Using Kaplan-Meier plotter, which is a large publicly available clinical breast cancer microarray database. High ILF2 mRNA expression was found to be an indicator of increased risk for relapse ($P = 8.6E-12$), distant metastasis ($P = 0.021$), and death ($P = 0.00061$; Figure 4A-C). This observation was also confirmed using three clinical cohorts from the Oncomine database (fold change $> 1.5$, $P < 0.05$), which showed that breast patients with elevated ILF2 mRNA levels had relatively low 1-, 3- and 5-year OS rates (Figure 4D-F).

High ILF2 expression predicted anthracycline/taxane-based neoadjuvant chemotherapy responses

BRCA proteins participate in DNA double-strand break (DSB) repair, and thus BRCA deficiencies increase genomic instability and promote the development of more aggressive tumour phenotypes [32, 33]. Oncomine analysis hinted that ILF2 expression was higher in BRCA1 mutation carriers compared with BRCA1 wildtype patients (fold change $= 1.597$, $P = 1.29E-4$; Figure 5A). Moreover, we also found that the ILF2 mRNA expression levels in pretreatment breast cancer biopsy specimens from chemo-sensitive patients were higher than in non-responders (fold change $= 1.469$, $P = 0.002$; Figure 5B).

BRCA1 mutation carriers show better responses to cytotoxic agents, which might be due to their deficiency in repairing the DNA DSBs induced by chemotherapy [34]. Additionally, based on the Oncomine results, ILF2 expression appears to be correlated with chemotherapy responses. Therefore, we further investigated correlations between ILF2 expression and che-
Clinicopathological significance of ILF2 in breast cancer

Table 2. AUC-ROC analysis of ILF2 expression in pretreatment biopsy specimens for predicting pCR

<table>
<thead>
<tr>
<th>GEO datasets</th>
<th>All patients</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>No. of pCR*</td>
<td>No. of non-pCR*</td>
<td>AUC*</td>
<td>P-value</td>
</tr>
<tr>
<td>GSE25055</td>
<td>306</td>
<td>57</td>
<td>249</td>
<td>0.745</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>GSE25065</td>
<td>182</td>
<td>42</td>
<td>140</td>
<td>0.687</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>GSE20194</td>
<td>278</td>
<td>56</td>
<td>222</td>
<td>0.677</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*p athological complete response. *area under the ROC curve.

Figure 6. Biological functions and upstream regulators associated with ILF2-related DEGs in breast cancer, by using IPA. A. The top 20 diseases and functions. Activated (white) and inhibited (black) ILF2-related biological functions are presented as -log (P-value) for the probability that the specific function is affected. The gray vertical line represent least significant differences (-log (P-value) = 1.301/P-value = 0.05). B. The predicted upstream regulators. C. The predicted regulatory network. IPA’s regulator effects algorithm connected the ILF2-related DEGs and predicted upstream regulators to downstream functions to generate regulator effects hypotheses with a consistency score. The diagram displays a result with high consistency score (15.50). Activated and inhibited regulators or functions are marked in orange and blue, respectively.

mo-responses in three larger GEO cohorts (GSE25055, GSE25065 and GSE20194) that received the commonly used anthracycline/taxane-based neoadjuvant chemotherapy regi- men. Breast cancer patients with higher levels of ILF2 expression in pre-treatment biopsy specimens were more likely to achieve pathological complete response (pCR) after anthra-
Clinicopathological significance of ILF2 in breast cancer

**Table 3.** The top 20 ILF2-related pathways from the IPA, based on most-significant P-values.

<table>
<thead>
<tr>
<th>Ingenuity Canonical Pathways</th>
<th>P-value</th>
<th>Ratio</th>
<th>Activation z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell cycle: G2/M DNA damage checkpoint regulation</td>
<td>5.89E-10</td>
<td>28.60%</td>
<td>-1.265</td>
</tr>
<tr>
<td>Protein ubiquitination pathway</td>
<td>5.89E-10</td>
<td>10.90%</td>
<td>NA</td>
</tr>
<tr>
<td>Sumoylation pathway</td>
<td>4.57E-06</td>
<td>14.60%</td>
<td>-1.265</td>
</tr>
<tr>
<td>RAN signaling</td>
<td>4.57E-06</td>
<td>41.20%</td>
<td>NA</td>
</tr>
<tr>
<td>Oxidative phosphorylation</td>
<td>1.41E-05</td>
<td>12.80%</td>
<td>NA</td>
</tr>
<tr>
<td>Mitochondrial dysfunction</td>
<td>0.00013</td>
<td>9.36%</td>
<td>NA</td>
</tr>
<tr>
<td>Estrogen-mediated S-phase entry</td>
<td>0.00069</td>
<td>25.00%</td>
<td>0.816</td>
</tr>
<tr>
<td>Mismatch repair in eukaryotes</td>
<td>0.001</td>
<td>31.20%</td>
<td>NA</td>
</tr>
<tr>
<td>Remodeling of epithelial adherens junctions</td>
<td>0.00107</td>
<td>13.00%</td>
<td>2.236</td>
</tr>
<tr>
<td>Cell cycle control of chromosomal replication</td>
<td>0.00112</td>
<td>17.50%</td>
<td>NA</td>
</tr>
<tr>
<td>Hypoxia signaling in the cardiovascular system</td>
<td>0.00155</td>
<td>12.20%</td>
<td>NA</td>
</tr>
<tr>
<td>Adipogenesis pathway</td>
<td>0.00182</td>
<td>8.96%</td>
<td>NA</td>
</tr>
<tr>
<td>Role of BRCA1 in DNA damage response</td>
<td>0.002</td>
<td>11.50%</td>
<td>-0.447</td>
</tr>
<tr>
<td>ATM signaling</td>
<td>0.00229</td>
<td>11.20%</td>
<td>0.378</td>
</tr>
<tr>
<td>Hereditary breast cancer signaling</td>
<td>0.00288</td>
<td>8.33%</td>
<td>NA</td>
</tr>
<tr>
<td>Mitotic roles of polo-like kinase</td>
<td>0.00288</td>
<td>12.10%</td>
<td>2</td>
</tr>
<tr>
<td>TCA cycle II (eukaryotic)</td>
<td>0.00302</td>
<td>21.70%</td>
<td>NA</td>
</tr>
<tr>
<td>Cholesterol biosynthesis I</td>
<td>0.00302</td>
<td>30.80%</td>
<td>NA</td>
</tr>
<tr>
<td>Cholesterol biosynthesis II (via 24, 25-dihydrolanosterol)</td>
<td>0.00302</td>
<td>30.80%</td>
<td>NA</td>
</tr>
<tr>
<td>Cholesterol biosynthesis III (via desmosterol)</td>
<td>0.00302</td>
<td>30.80%</td>
<td>NA</td>
</tr>
</tbody>
</table>

cycline/taxane-based neoadjuvant treatment in all three datasets (GSE25055, GSE25065 and GSE20194), with area under the ROC curve (AUC) values of 0.745 (P < 0.001), 0.687 (P < 0.001) and 0.677 (P < 0.001), respectively (Figure 5C-E; Table 2). These results indicated that ILF2 expression maybe a predictive biomarker for better responses to anthracycline/taxane-based treatment in breast cancer patients.

**IPA reveals potential ILF2 regulatory mechanisms**

We used IPA software to analyse the 592 ILF2-related differentially expressed genes (DEGs) (29 downregulated and 563 upregulated) and found multiple statistically significant related biological functions (P < 0.05), the top 20 of which are presented in Figure 6A. The most affected biological functions in high ILF2-expressing breast cancer tissues were involved in promoting cell survival, viability and proliferation. Additionally, the IPA software also predicted that ILF2 overexpression was correlated with “cell cycle progression”, “viral infection”, “repair of DNA” and “metabolism of protein”.

To more deeply explore the relevant mechanisms underlying ILF2-related biological functions, we identified 44 canonical pathways (P < 0.05), and the top 20 most significant pathways are listed in Table 3. Consistent with the observations above, these DEGs were highly enriched for pathways related to cell cycle progression such as “Cell Cycle: G2/M DNA Damage Checkpoint Regulation”, “Estrogen-mediated S-phase Entry”, “Cell Cycle Control of Chromosomal Replication” and “Mitotic Roles of Polo-Like Kinase”. To further elucidate the role of ILF2 in G2/M transition, we explored correlations between ILF2 expression and several cell cycle regulators using TCGA breast dataset from Oncomine. Activated Cyclin A/B-CDK1 complex is essential for G2/M phase progression [35]. Polo-like kinase 1 (PLK1) and Aurora A are well-established regulators of mitotic progression, and their hyperactivity can override DNA damage-induced G2 checkpoint arrest [36-38]. We found that ILF2 mRNA levels in breast cancer tissues are positively correlated with those of CCNA2 (Cyclin A2), CCNB1 (Cyclin B1), CDK1, AURKA (Aurora A), AURKB (Aurora B) and PLK1 (Supplementary Figure 1). DEGs were also enriched for pathways related to DNA repair, such as “Mismatch Repair in Eukaryotes”, “Role of BRCA1 in DNA Damage Response” and “ATM Signalling”. Additionally, we observed that pathways involved in energy
metabolism and biosynthesis were changed, including “Oxidative Phosphorylation”, “Mitochondrial Dysfunction”, “Adipogenesis pathway”, “TCA Cycle” and “Cholesterol Biosynthesis”. Overactivation of “Remodelling of Epithelial Adherens Junctions” implied that breast cancers with high ILF2 expression might possess strong invasive ability.

IPA upstream analysis was used to predict which upstream regulators might be activated or inhibited to explain the gene expression changes caused by ILF2 expression. Several transcriptional regulators were predicted (z-score value ≥ 2 for activation and ≤ -2.0 for inhibition; P < 0.05), and the top 10 activated or inhibited upstream regulators are shown in Figure 6B. Regarding activated upstream regulators, except for certain well-known oncogenes such as MYC and HGF, activation of two of the most well-studied molecules involved in breast cancer, i.e., ESR1 and ERBB2, were also predicted, which implied that ILF2 might participate in the progression of luminal and HER2-positive breast cancer by activating the oestrogen pathway and ERBB2 pathway, respectively. Moreover, we noticed that several highly significant predicted upstream regulators were cytokines (such as CSF2, IFNG and IL5). Considering the role that ILF2 plays in the transcription of IL2 and IL13 in T cells [6, 39], we hypothesize that additional communication occurs between breast cancer cells and tumour-infiltrating lymphocytes in breast cancer tissues with high ILF2 expression. With respect to inhibited upstream regulators, the upstream analysis revealed several microRNAs, such as miR-21, miR-155-5p and let-7. ILF2 has been reported to inhibit the maturation of several microRNAs, including let-7, miR-21 [10], miR-133a [11] and miR-7 [12], by restraining primary miRNA processing into precursor miRNAs. miR-21 (activation z-score = -5.041), let-7 (activation z-score = -3.604), and miR-133a-3p (activation z-score = -2.938) were also identified as upregulated regulators in the IPA upstream analysis, which adds confidence to the reliability of this method. Other predicted downregulated microRNAs such as miR-155-5p (activation z-score = -3.719), miR-1-3p (activation z-score = -3.225) and miR-124-3p (activation z-score = -3.141), which have been reported to influence breast cancer progression [40-42], might be novel ILF2 substrates.

Finally, causal networks were constructed to connect the DEGs and the predicted upstream regulators to downstream functions. Figure 6C illustrates one of the top mechanistic hypotheses that explains the expression changes observed in datasets grouped by ILF2 levels.

Discussion

Due to both inter- and intra-tumoral heterogeneity in breast cancer, patients with the same tumour stage or grade can have different therapeutic responses, metastatic patterns, and/or clinical outcomes. Fortunately, the development of molecular oncology has identified several biomarkers that can provide additional information about the intrinsic characteristics of individual breast cancer patients. Some of them (e.g., ER, HER2) have been widely used in the clinic to predict patient outcomes and serve as therapeutic targets. ILF2 forms a heterodimeric core complex with NF90, which binds to nucleic acids, altering gene expression at multiple levels. In this work using publicly available clinical datasets, we found that ILF2 was involved in the development and progression of breast cancer and may be a predictive biomarker for better anthracycline/taxane-based treatment responses.

ILF2 is located on chromosome 1q21 [39], a region frequently amplified in breast cancer [43, 44]. We found that ILF2 copy number gain was present in 3.14% of breast cancer patients and that there was higher ILF2 mRNA expression in breast cancer tissues compared with normal breast tissues. Using publicly available clinical datasets with large sample sizes, we further showed that elevated ILF2 expression was correlated with some aggressive features, such as high histological grade, BRCA1 mutations, the triple-negative/basal-like subtype, and shorter RFS, DMSF and OS. IPA indicated that ILF2-related DEGs were enriched in biological functions involved in promoting cell survival, viability, proliferation and inhibiting cell death, necrosis and apoptosis. Further analysis showed that several pathways correlated with cell cycle progression and DNA repair were also altered. These findings are consistent with observations in other cancer types. Depletion of the ILF2/NF90 complex sensitizes cervical carcinoma cells to genotoxic drug-induced apoptosis by restoring p53 expression.
via reducing HPV-E6 RNA expression [45]. Zheng et al. [18] also reported that ILF2 blocked apoptosis in liver cancer cells by upregulating the anti-apoptotic proteins Bcl-2 and clAP1, and downregulating the pro-apoptotic proteins Bax, Bak, and Bok. However, ILF2 also stimulates cell proliferation by promoting cell cycle progression in non-small cell lung cancer [19], pancreatic carcinoma [16], oesophageal squamous cell carcinoma [20], and glioma [46] cells.

MicroRNAs are short non-coding RNAs that regulate many crucial cancer-related pathways by post-transcriptionally silencing mRNAs [47]. The intimate and complicated relationship between ILF2 and microRNAs was also revealed in cancer cells. Sakamoto et al. [12] found that the NF90/ILF2 complex promoted the proliferation of hepatocellular carcinoma cells by restraining mIR-7 biogenesis. ILF2 also inhibited the maturation of let-7, miR-21, and miR-133a [10, 11], which are known to affect cancer progression [48-50]. However, ILF2 expression is also regulated by microRNAs. Recently, a study reported that miR-7 reduced ILF2 expression and regulated epithelial-mesenchymal transition-related genes in pancreatic carcinoma [17]. Similarly, we observed that several microRNAs, including miR-155-5p, miR-1-3p, miR-124-3p, and some of the previously reported ILF2-regulated microRNAs (miR-21, let-7, and miR-133a-3p) were predicted to be inhibited upstream regulators of the ILF2-related expression network in breast cancer. This result indicated that ILF2-induced breast cancer progression may partially rely on interactions with microRNAs.

In this study, we also found that breast cancer patients with elevated ILF2 expression were more likely to achieve pCR after anthracycline/taxane-based neoadjuvant treatment. Unlike our study, Colla et al. [9] found that depleting ILF2 increased the sensitivity of multiple myeloma cells to DNA damaging agents by affecting YB-1 nuclear localization and thereby decreasing homologous recombination repair. The IPA results offer certain clues to explain the contradictory effects of ILF2 on multiple myeloma and breast cancer. After DNA damage caused by chemotherapy or radiotherapy, cell cycle arrest at the G2/M checkpoint allows DNA repair. Interestingly, previous research has shown that ILF2 plays roles in both cell cycle progression and DNA repair. According to our IPA results, although selected pathways involved in DNA repair were disrupted, a clearer trend towards promoting cell cycle progression can be observed in breast cancer. We found that upregulated ILF2 expression was correlated with downregulation of the G2/M DNA damage checkpoint and PLK pathway activation. Additionally, we observed that elevated ILF2 expression in breast cancer tissues was positively correlated with the expression of CCNA2, CCNB1, CDK1, AURKA, AURKB and PLK1, which are mitotic inducers and checkpoint regulators. Taken together, these data suggest that ILF2 overexpression may lead to defective checkpoint control, which causes cell cycle progression and the loss of genomic integrity in breast cancer. As G2/M checkpoint defects have been confirmed to contribute to the sensitivity to DNA damaging agents [51], the higher pCR rates in breast cancer patients with elevated ILF2 expression was consistent with previous studies. However, breast cancer patients with higher expression of proliferation genes have been confirmed to contribute to the sensitivity to DNA damaging agents [52], thus ILF2-induced cellular proliferation could also lead to increased pCR rates. Although more breast cancers with elevated ILF2 expression respond to chemotherapy initially, early relapses occur because of genomic instability caused by overriding the checkpoint.

Finally, we are the first group to investigate the roles of ILF2 in breast cancer development and progression. This study benefited from a large sample size facilitated by publicly available online datasets, which offer opportunities to derive more reliable and precise results. Gene expression data used in IPA were sourced from pre-treatment tumour biopsies from clinical breast cancer cases, and hence interactions between various cell types in the tumour microenvironment could be explored. This approach might be more suitable because ILF2 has been found to regulate cytokine synthesis in lymphocytes [6, 39]. Nevertheless, certain limitations in our study should be considered when interpreting the results. First, all results are based on ILF2 expression at the mRNA level; future protein-level investigations are warranted. Moreover, ILF2-related biological functions, canonical pathways and upstream regulators were calculated based on prior biological knowledge in the IPA ingenuity knowl-
Clinicopathological significance of ILF2 in breast cancer

edge database. These findings must be further confirmed by mechanistic studies performed in breast cancer cells.

In conclusion, we showed that ILF2 may be involved in breast cancer carcinogenesis and that elevated ILF2 expression was correlated with certain aggressive features in breast cancer, such as high histological grade, BRCA1 mutations and the triple-negative/basal-like subtype. More importantly, ILF2 can help select breast cancer patients who are likely to benefit from anthracycline/taxane-based neoadjuvant chemotherapy.

Acknowledgements

This work was supported by Subject Development Project of China Medical University (No. 3110117053) and National Natural Science Foundation Project (No. 81372811).

Disclosure of conflict of interest

None.

Address correspondence to: Bo Chen, Department of Breast Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang 110001, Liaoning Province, China. E-mail: chbyxl@163.com

References


[15] Guan D, Altan-Bonnet N, Parrott AM, Arrigo CI, Li Q, Khaleduzzaman M, Li H, Lee CG, Pe’ery T and Mathews MB. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with
Clinicopathological significance of ILF2 in breast cancer


Clinicopathological significance of ILF2 in breast cancer


Supplementary Figure 1. Levels of ILF2 mRNA expression in breast cancer tissues are positively correlated with those of CCNA2 (A), CCNB1 (B), CDK1 (C), AURKA (D), AURKB (E) and PLK1 (F), based on TCGA breast dataset obtained from Oncomine.